Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07530250 · ClinicalTrials.gov registry record · NA
Assessing Two Coenzyme Q10 Products in Men and Women
A NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT07530250: Recruiting NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
NCT07530250 is a NA study that is actively recruiting participants, run by Midwest Center for Metabolic and Cardiovascular Research. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07530250, a NA study, is actively recruiting participants, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to compare the relative bioavailability of coenzyme Q10 (CoQ10) from acute administrations of a CoQ10 product designed for enhanced absorption versus a standard CoQ10 product in healthy men and women. Participants will be asked to come to the clinical on five different occasions, including a screening visit (visit 1, -7 days), two test 1 visits (visits 2 and 3, days 0 and 1), and two test 2 visits (visits 4 and 5, days 7 and 8). During the start of each test visit (visits 2 and 4), the participant will consume each study product with water and a standardized breakfast meal. Then, blood samples will be collected over a 10-hour period, and a standardized lunch, dinner, and snacks will be provided. The participant will return to the clinic the next morning for a blood draw 24 hours after the study product ingestion from the previous day. The same procedures will be repeated 7 to 14 days later with the other study product.
Primary Outcome
Difference between conditions in the niAUC for plasma CoQ10 from 0 to 24 h where t = 0 is the time of study product ingestion
Interventions
- DIETARY_SUPPLEMENT high absorption CoQ10 product
- DIETARY_SUPPLEMENT standard CoQ10 product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2026-07 |
| Phase | NA |
What NCT07530250 shows while recruiting
NCT07530250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which high absorption CoQ10 product is the first listed.
NCT07530250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07530250 about?
NCT07530250 is a clinical study titled "Assessing Two Coenzyme Q10 Products in Men and Women". The goal of this clinical trial is to compare the relative bioavailability of coenzyme Q10 (CoQ10) from acute administrations of a CoQ10 product designed for enhanced absorption versus a standard CoQ10 product in healthy men and women. Participants will be asked to come to the clinical on five diffe...
What is the current status of trial NCT07530250?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2026-05-18. Estimated completion is 2026-07.
What interventions are being tested in trial NCT07530250?
The interventions under investigation include: high absorption CoQ10 product (DIETARY_SUPPLEMENT), standard CoQ10 product (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07530250?
This trial is sponsored by Midwest Center for Metabolic and Cardiovascular Research, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07530250's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI